60 Degrees shares surge 40.16% intraday after trial shows 100% cure rate in babesiosis patients with tafenoquine.

60 Degrees Pharmaceuticals surged 40.16% intraday after announcing that all three patients in its trial of tafenoquine for relapsing babesiosis in immunosuppressed patients were cured. The open-label study confirmed a 100% cure rate when tafenoquine was combined with atovaquone and other antimalarials, aligning with a 2024 Yale study showing similar results in seven total cases. The company emphasized the potential for updated treatment guidelines and highlighted tafenoquine’s efficacy in a high-risk, underserved patient population. Despite tafenoquine’s current FDA approval only for malaria prophylaxis, the data underscore its therapeutic potential for babesiosis, a disease lacking approved treatments. The dramatic price increase reflects investor optimism about the drug’s future regulatory and commercial prospects.